161 related articles for article (PubMed ID: 37500985)
21. Effects of Postoperative Day and NR1I2 on Tacrolimus Clearance in Chinese Liver Transplant Recipients-A Population Model Approach.
Lu Y; Xu L; Cui J; Shen S; Li X
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1385-1394. PubMed ID: 34133842
[TBL] [Abstract][Full Text] [Related]
22. A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk.
Campa D; Butterbach K; Slager SL; Skibola CF; de Sanjosé S; Benavente Y; Becker N; Foretova L; Maynadie M; Cocco P; Staines A; Kaaks R; Boffetta P; Brennan P; Conde L; Bracci PM; Caporaso NE; Strom SS; Camp NJ; Cerhan JR; ; Canzian F; Nieters A
Int J Cancer; 2012 Aug; 131(4):803-12. PubMed ID: 21918980
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism.
Fujiwara Y; Hamada A; Mizugaki H; Aikawa H; Hata T; Horinouchi H; Kanda S; Goto Y; Itahashi K; Nokihara H; Yamamoto N; Ohe Y
Cancer Sci; 2016 Aug; 107(8):1117-23. PubMed ID: 27270784
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients.
Liu F; Ou YM; Yu AR; Xiong L; Xin HW
Genet Test Mol Biomarkers; 2017 Nov; 21(11):663-673. PubMed ID: 28945481
[TBL] [Abstract][Full Text] [Related]
25. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
Chew SC; Singh O; Chen X; Ramasamy RD; Kulkarni T; Lee EJ; Tan EH; Lim WT; Chowbay B
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1471-8. PubMed ID: 21468756
[TBL] [Abstract][Full Text] [Related]
26. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.
Miura M; Kagaya H; Satoh S; Inoue K; Saito M; Habuchi T; Suzuki T
Ther Drug Monit; 2008 Oct; 30(5):559-64. PubMed ID: 18695635
[TBL] [Abstract][Full Text] [Related]
27. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma.
Hegyi M; Arany A; Semsei AF; Csordas K; Eipel O; Gezsi A; Kutszegi N; Csoka M; Muller J; Erdelyi DJ; Antal P; Szalai C; Kovacs GT
Oncotarget; 2017 Feb; 8(6):9388-9398. PubMed ID: 27566582
[TBL] [Abstract][Full Text] [Related]
29. Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer.
Ozeki T; Nagahama M; Fujita K; Suzuki A; Sugino K; Ito K; Miura M
Sci Rep; 2019 Apr; 9(1):5404. PubMed ID: 30931962
[TBL] [Abstract][Full Text] [Related]
30. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
Tamura M; Kondo M; Horio M; Ando M; Saito H; Yamamoto M; Horio Y; Hasegawa Y
Nagoya J Med Sci; 2012 Feb; 74(1-2):133-40. PubMed ID: 22515119
[TBL] [Abstract][Full Text] [Related]
31. Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
Akasaka K; Kaburagi T; Yasuda S; Ohmori K; Abe K; Sagara H; Ueda Y; Nagao K; Imura J; Imai Y
Cancer Chemother Pharmacol; 2010 Sep; 66(4):691-8. PubMed ID: 20035425
[TBL] [Abstract][Full Text] [Related]
32. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
Rudin CM; Liu W; Desai A; Karrison T; Jiang X; Janisch L; Das S; Ramirez J; Poonkuzhali B; Schuetz E; Fackenthal DL; Chen P; Armstrong DK; Brahmer JR; Fleming GF; Vokes EE; Carducci MA; Ratain MJ
J Clin Oncol; 2008 Mar; 26(7):1119-27. PubMed ID: 18309947
[TBL] [Abstract][Full Text] [Related]
34. Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan.
Kim CO; Cho SK; Oh ES; Park MS; Chung JY
J Cardiovasc Pharmacol; 2012 Jul; 60(1):49-54. PubMed ID: 22494992
[TBL] [Abstract][Full Text] [Related]
35. Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib.
Kobayashi H; Sato K; Niioka T; Takeda M; Okuda Y; Asano M; Ito H; Miura M
Med Oncol; 2016 Jun; 33(6):57. PubMed ID: 27154635
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer.
Mizugaki H; Oizumi S; Fujita Y; Harada T; Nakahara Y; Takashina T; Ko R; Watanabe K; Hotta T; Minemura H; Saeki S; Asahina H; Nakamura K; Nakamura H; Hosoda F; Yagishita S; Hamada A
Eur J Cancer; 2022 Jan; 160():227-234. PubMed ID: 34862083
[TBL] [Abstract][Full Text] [Related]
37. Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.
Brown KC; Hosseinipour MC; Hoskins JM; Thirumaran RK; Tien HC; Weigel R; Tauzie J; Shumba I; Lamba JK; Schuetz EG; McLeod HL; Kashuba AD; Corbett AH
Pharmacogenomics; 2012 Jan; 13(1):113-21. PubMed ID: 22111602
[TBL] [Abstract][Full Text] [Related]
38. Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin.
Chung JY; Cho JY; Lim HS; Kim JR; Yu KS; Lim KS; Shin SG; Jang IJ
Drug Metab Dispos; 2011 Jan; 39(1):92-7. PubMed ID: 20876786
[TBL] [Abstract][Full Text] [Related]
39. Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study.
Ishikawa E; Yokoyama Y; Chishima H; Kasai H; Kuniyoshi O; Kimura M; Hakamata J; Nakada H; Suehiro N; Nakaya N; Nakajima H; Ikemura S; Kawada I; Yasuda H; Terai H; Jibiki A; Kawazoe H; Soejima K; Muramatsu H; Suzuki S; Nakamura T
Invest New Drugs; 2023 Feb; 41(1):122-133. PubMed ID: 36637703
[TBL] [Abstract][Full Text] [Related]
40. ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib.
Sakamoto S; Sato K; Takita Y; Izumiya Y; Kumagai N; Sudo K; Hasegawa Y; Yokota H; Akamine Y; Okuda Y; Asano M; Takeda M; Sano M; Miura M; Nakayama K
Invest New Drugs; 2020 Dec; 38(6):1687-1695. PubMed ID: 32436059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
